Free Submission Public Relations & NewsPR-inside.com
Home
Deutsch English

Health

Hereditary Angioedema (HAE) - Pipeline Review, H2 2013: New research report available at Fast Market Research


Print article Print article
2013-12-22 00:11:29 - Recently published research from Global Markets Direct, "Hereditary Angioedema (HAE) - Pipeline Review, H2 2013", is now available at Fast Market Research

Global Markets Direct's, 'Hereditary Angioedema (HAE) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Hereditary Angioedema (HAE), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hereditary Angioedema (HAE). Hereditary Angioedema (HAE) - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Full Report Details at
- www.fastmr.com/prod/755155_hereditary_angioedema_hae_pipeline_re ..

Note*: Certain sections in the report may be removed or altered based

on the availability and relevance of data for the indicated disease.

Scope

* A snapshot of the global therapeutic scenario for Hereditary Angioedema (HAE).
* A review of the Hereditary Angioedema (HAE) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
* Coverage of products based on various stages of development ranging from discovery till registration stages.
* A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
* Coverage of the Hereditary Angioedema (HAE) pipeline on the basis of route of administration and molecule type.
* Key discontinued pipeline projects.
* Latest news and deals relating to the products.

Reasons to Get this Report

* Identify and understand important and diverse types of therapeutics under development for Hereditary Angioedema (HAE).
* Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
* Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
* Devise corrective measures for pipeline projects by understanding Hereditary Angioedema (HAE) pipeline depth and focus of Indication therapeutics.
* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
* Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Companies Mentioned in this Report: Isis Pharmaceuticals, Inc., Pharming Group N.V., Dyax Corp., ViroPharma Incorporated, BioCryst Pharmaceuticals, Inc., CSL Limited, iBio, Inc.

Partial Table of Contents:

Table of Contents
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Hereditary Angioedema (HAE) Overview
Therapeutics Development
An Overview of Pipeline Products for Hereditary Angioedema (HAE)
Hereditary Angioedema (HAE) Therapeutics under Development by Companies
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Hereditary Angioedema (HAE) Therapeutics - Products under Development by Companies
Companies Involved in Hereditary Angioedema (HAE) Therapeutics Development
Isis Pharmaceuticals, Inc.
Pharming Group N.V.
Dyax Corp.
ViroPharma Incorporated
BioCryst Pharmaceuticals, Inc.
CSL Limited
iBio, Inc.
Hereditary Angioedema (HAE) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
conestat alfa - Drug Profile
Product Description
Mechanism of Action
R&D Progress
conestat alfa - Drug Profile
Product Description
Mechanism of Action
R&D Progress
C1 esterase inhibitor (human) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
conestat alfa - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BCX-4161 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
C1-Esterase Inhibitor - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DX-2930 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CSL-830 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Hereditary Angioedema Program - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ISIS-PKK - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Second Generation Plasma Kallikrein Inhibitor - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cyclomimetic - Drug Profile
Product Description
Mechanism of Action
R&D Progress
EZN-3008 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drug For Hereditary Angioedema - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Hereditary Angioedema (HAE) Therapeutics - Drug Profile Updates
Hereditary Angioedema (HAE) Therapeutics - Discontinued Products
Hereditary Angioedema (HAE) Therapeutics - Dormant Products
Hereditary Angioedema (HAE) - Product Development Milestones
Featured News & Press Releases
Nov 12, 2013: Analysis of Pivotal Study Data Showed Routine Prevention of Hereditary Angioedema (HAE) Attacks with Cinryze (C1 esterase inhibitor [human]) Resulted in Improved Health-Related Quality of Life Outcomes Compared to Acute Therapy with C1 Inhibitor While On Placebo
Nov 08, 2013: Santarus and Pharming Announce New Data from Open-Label Repeat Treatment Study with RUCONEST
Nov 06, 2013: ViroPharma Announces Upcoming Data Presentations at the 2013 American College of Allergy, Asthma and Immunology Annual Scientific Meeting

Full Table of Contents is available at:
-- www.fastmr.com/catalog/product.aspx?productid=755155&dt=t

About Global Markets Direct

Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. View more research from Global Markets Direct at www.fastmr.com/catalog/publishers.aspx?pubid=1033

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.


Author:
Bill Thompson
e-mail
Web: www.fastmr.com
Phone: 18008448156

Disclaimer: If you have any questions regarding information in these press releases please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims contents contained in this release.
Latest News
Read the Latest News
www.newsenvoy.com

 


Terms & Conditions | Privacy | About us | Contact PR-inside.com